Home » J&J Is Short of Cancer Drug Doxil
J&J Is Short of Cancer Drug Doxil
Johnson & Johnson is warning doctors not to start new patients on its cancer drug Doxil due to a supply shortage — the latest in a series of shortages from various drug makers that have hamstrung health-care providers.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct